Mixed Bag for Semaglutide in NASH-Related Compensated Cirrhosis

(MedPage Today) -- Although semaglutide (Ozempic) missed its mark in improving liver fibrosis for patients with nonalcoholic steatohepatitis (NASH)-related cirrhosis, improvements were noted in cardiometabolic parameters and other biomarkers, according...
Source: MedPage Today Endocrinology - Category: Endocrinology Source Type: news